Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti‐Interferon‐α Receptor Antibody

E-ISSN： 1532-6535|93|6|483-492

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.93, Iss.6, 2013-06, pp. : 483-492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐α

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 1996-08 ,pp. : 300-305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Neutralizing anti‐interferon‐α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon‐α

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 2, 1996-08 ,pp. : 300-305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 182, Iss. 2, 2015-11 ,pp. : 139-148

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 193-200

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab on Cholangiocarcinoma of the Liver

Oncology Research and Treatment, Vol. 30, Iss. 3, 2007-02 ,pp. : 129-131

Karger

Access to resources Recommend Favorite